Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2026-03-17

FDA Approved: ORKAMBI — Supplemental Application (Vertex Pharmaceuticals Incorporated)

View source ↗

Summary

The FDA approved a supplemental application for ORKAMBI (lumacaftor/ivacaftor) by Vertex Pharmaceuticals.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ORKAMBI (lumacaftor and ivacaftor)

Snippet

SUPPL AP for ORKAMBI (LUMACAFTOR AND IVACAFTOR)